John Cox
Chief Executive Officer at DYNE THERAPEUTICS, INC.
Net worth: 188 019 $ as of 2023-07-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Douglas Cole | M | 63 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 9 years |
Jason Rhodes | M | 54 | 7 years | |
Josias Fantato De Pontes | M | 58 | 5 years | |
Tony Hunt | M | 60 | 10 years | |
Bart Henderson | M | 65 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
Caroline Dorsa | F | 64 | 14 years | |
Nicolas Barthelemy | M | 58 | 19 years | |
Rick Scalzo | M | 38 | 5 years | |
Natalie Yivgi-Ohana | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Nicole Murphy | F | - | 9 years | |
Michael Hencke | M | - | 12 years | |
James Bylund | M | 61 | 4 years | |
Stephen Sherwin | M | 75 | 14 years | |
Steve Curran | M | - | 9 years | |
Philip Johnson | M | 59 | 1 years | |
Catherine Stehman-Breen | M | 61 | 5 years | |
Molly White | F | 64 | 4 years | |
Mahalakshmi Radhakrishnan | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 5 years |
John Najim | M | 48 | 5 years | |
Amy Reilly | F | 51 | 4 years | |
Ephraim Aharonson | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Carlo Incerti | M | 65 | 2 years | |
David Lubner | M | 60 | 4 years | |
Eric Rowinsky | M | 67 | 14 years | |
Edward Hurwitz | M | 60 | 6 years | |
Michael Thompson | M | - | 1 years | |
Glenn Muir | M | 65 | 9 years | |
Qing Sarah Yuan | M | 53 | 5 years | |
Uriel Halavee | M | - |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Dirk Kersten | M | 49 | 6 years | |
Timothy Harris | M | 74 | 9 years | |
Rohin Mhatre | M | 59 | 4 years | |
Lisa Butterfield | F | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | - |
Thomas-Christian Mix | M | 57 | 4 years | |
Daniel Wilson | M | 53 | 4 years | |
Robert Windsor | M | - | 3 years | |
Debra Feldman | F | 54 | 4 years | |
John Davis | M | 56 | 4 years | |
Ralf Kuriyel | M | 66 | 8 years | |
Jonathan McNeill | M | 39 | 5 years | |
Shmuel Cabilly | M | 74 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | - |
B. Parshall | F | 70 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 years |
Steven Harr | M | 53 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 4 years |
Susan Hockfield | M | 73 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 years |
Douglas A. Lauffenburger | M | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 8 years |
Torben Nissen | M | 53 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 2 years |
Susanna High | F | 56 | 4 years | |
Anne Walker | F | 49 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 years |
Oxana Beskrovnaya | M | 63 | 4 years | |
Ashish Dugar | M | - | 3 years | |
Wildon Farwell | M | 49 | 3 years | |
Zeev Milbauer | M | 69 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 12 years |
Stephen Berenson | M | 63 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 3 years |
Christine Gebski | F | 56 | 9 years | |
Gordon Brooks | M | - | 1 years | |
Philip Ashton-Rickardt | M | 60 | 3 years | |
Chris Anderson | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Walter C. Herlihy | M | 72 | 19 years | |
Robert Essner | M | 76 |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | 11 years |
V. Lawlis | M | 72 |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 5 years |
William Kelly | M | 53 | 6 years | |
Joshua Brumm | M | 46 | 5 years | |
James Mullen | M | 65 |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | 23 years |
Andrea DiFabio | F | 55 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 14 years |
Daniel Anderson | M | - | 6 years | |
Jose-Carlos Gutiérrez-Ramos | M | 61 |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | 2 years |
Michel Vounatsos | M | 62 | 6 years | |
Glenn M. Reicin | M | 59 | 2 years | |
Alexander Denner | M | 54 | 14 years | |
Brian Posner | M | 62 | 14 years | |
Stelios Papadopoulos | M | 75 | 15 years | |
William Young | M | 79 | 11 years | |
William Rastetter | M | 75 | 19 years | |
Jon Snodgres | M | 58 | 9 years | |
Diantha Duvall | F | 52 | 4 years | |
Martha Rook | F | 53 | 4 years | |
Carlos Costa | M | 51 | 7 years | |
Vanya Sagar | F | 49 | 6 years | |
Trevor Anthony Mill | M | 53 | 9 years | |
Kavita Patel | M | 50 | 3 years | |
Samantha Truex | F | - | 8 years | |
Brooke Story | F | 52 | 1 years | |
John Greene | M | 58 | 2 years | |
Eric Shaff | M | 48 | 6 years | |
Glenn L. Cooper | M | 71 | 11 years | |
John Scarlett | M | 73 |
Covance Biotechnology Services, Inc.
Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | 5 years |
Geno Germano | M | 63 | - | |
Richard Mulligan | M | 69 | 14 years | |
Robert A. Hamm | M | 72 | 7 years | |
Jonathan Lieber | M | 54 | 2 years | |
Stephen Oesterle | M | 73 | 7 years | |
Gregory Covino | M | 59 | 6 years | |
Phillip Sharp | M | 79 | 31 years | |
Fred Hassan | M | 78 |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | 4 years |
Michael Gilman | M | 69 | 8 years | |
Robert Ruffolo | M | 74 | 7 years | |
Craig Eric Schneier | M | 76 | 8 years | |
Nancy L. Leaming | F | 76 | 14 years | |
Bethany Sensenig | F | 48 |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | 16 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 94 | 94.95% |
Israel | 7 | 7.07% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Cox
- Personal Network